InflaRx NV
IFRX
View Detailed Chart
1.270USD
-0.110-7.97%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
86.04MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-7.97%
5 Days
-23.49%
1 Month
-19.62%
6 Months
-26.59%
Year to Date
-48.58%
1 Year
-19.62%
View Detailed Chart
TradingKey Stock Score of InflaRx NV
Currency: USD Updated: 2025-11-03Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
InflaRx NV's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
4.143
Target Price
+183.76%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
InflaRx NV Highlights
StrengthsRisks
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Growing
The company is in a growing phase, with the latest annual income totaling USD 152.79K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 152.79K.
Fairly Valued
The company’s latest PE is -2.23, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.71M shares, decreasing 24.47% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.71.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
InflaRx NV Info
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Ticker SymbolIFRX
CompanyInflaRx NV
CEOProf. Niels C. Riedemann, M.D., Ph.D
Websitehttps://www.inflarx.de/
Related Instruments
+0.63%
-1.86%
-1.32%
-12.62%
-0.86%
+0.84%
+0.09%
-4.76%
+3.90%
-4.01%
+3.61%
-3.45%
-1.05%
-1.28%
-0.42%
+7.83%
-3.46%
-0.26%
-0.54%
-4.90%Popular Symbols
